Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study

Abstract

Objectives: We investigated the time course of clinical response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study (TEOSS). Methods: TEOSS randomized 119 predominantly outpatient youth ages 8-19 years with schizophrenia or schizoaffective disorder to 8 weeks of treatment with molindone, risperidone, or olanzapine. We used proportional hazards regression to determine whether these three antipsychotics differed in the time until clinical response, defined as the time from treatment initiation to the point of achieving a Clinical Global Impressions-Improvement (CGI-I) scale score of 1 (''very much improved'') or 2 (''much improved'') that was maintained until week 8. Results: Of the 116 youth who initiated treatment, 56 (48%) achieved clinical response. Among clinical responders, the median (-interquartile range) time until clinical response was 4.0 (-4.0) weeks for olanzapine, 4.5 (-4.0) weeks for risperidone, and 6.0 (-4.0) weeks for molindone. There were no significant differences in time course for clinical response between medications ( p = 0.84). Youth without symptom improvement (CGI-I ‡ 4) after 3 weeks were more likely to be clinical nonresponders at week 8 (relative risk ratio = 1.98, 95% confidence interval 1.29-3.05), compared with youth with atleast-minimal symptom improvement after 3 weeks when looking at all antipsychotics combined. Conclusion: To our knowledge, our study is the first to investigate medication differences in treatment response timing in early onset schizophrenia spectrum disorders. Clinical response times for molindone, risperidone, and olanzapine were not significantly different. Furthermore, while lack of early improvement predicted clinical nonresponse, whether or not to continue antipsychotic treatment after 3 or more weeks without symptom improvement should be based on clinical judgment after weighing potential risks, benefits, and alternatives. ClinicalTrials.gov Identifier: NCT00053703

Efficacy and Safety of Second-generation Antipsychotics in Schizophrenia Pharmacotherapy: A Comparative Narrative Review

“…Overall, time to clinical response did not differ significantly across several SGAs, thus opening the role of clinical judgement and balancing benefits and risks in individual cases (6). Dose-dependent antipsychotic effectiveness has been observed in schizophrenia during the acute phase of the illness, where every antipsychotic has its own unique dose-response curve (7).…”

Utilization of Polymeric Micelles as a Lucrative Platform for Efficient Brain Deposition of Olanzapine as an Antischizophrenic Drug via Intranasal Delivery

“…Schizophrenia is a mental disorder characterized by hallucinations, alterations in cognition, behavior, emotion, and disorganized speech that severely cause distress and daily functional impairment [1,2]. Approximately 23 million people worldwide are suffering from schizophrenia, 1% of whom are in adolescence or early adulthood [3,4].…”

Commentary: Schizophrenia prevention and prodromal psychosis in children and adolescents

“…Schizophrenia is a brain disorder characterized by hallucinations, delusions, and/or disorganized speech that cause distress and functional impairment. Antipsychotics are the gold‐standard treatment for schizophrenia; however, antipsychotics have many side effects and only provide partial symptom relief (Taylor, Appel, et al, 2020; Taylor, Jakubovski, Gabriel, & Bloch, 2018). Therefore, efforts to prevent schizophrenia are warranted.…”